Chitosan in the Fight Against Resistant Pathogens: A Promising Nanocomposite

Antibiotic resistance is on the rise worldwide. Even well-established drugs are increasingly failing against dangerous pathogens such as MRSA, Klebsiella pneumoniae or Candida albicans. The development of novel antimicrobial systems is therefore more urgent than ever.

One highly innovative approach now combines three powerful components in a single nanocomposite: vancomycin, zinc oxide nanoparticles (ZnO-NPs) and chitosan (CS). The study shows that this combination acts synergistically – and significantly outperforms conventional single agents in terms of antimicrobial efficacy.

Triple Action Through Intelligent Design

The nanocomposite developed in the study is based on a well-balanced three-component system:
Vancomycin: a well-established reserve antibiotic, primarily active against Gram-positive bacteria
Zinc oxide nanoparticles: generate reactive oxygen species and damage microbial membranes
Chitosan: not only acts as a carrier material, but also actively enhances the antimicrobial effect

Each component complements the others functionally. While vancomycin specifically disrupts bacterial cell wall synthesis, ZnO nanoparticles attack the microbial membrane. Chitosan, as a bioactive polymer, improves the stability and controlled release of the active ingredients and enhances binding to negatively charged microbial surfaces through its positive surface charge.

High-Purity Chitosan as a Key Component

The study used a chitosan with a degree of deacetylation ≥ 85% and a molecular weight of 50–190 kDa (sourced from Sigma-Aldrich). These parameters are crucial for:

• good water solubility
• high bioavailability
• strong electrostatic interactions with microbial cell membranes

Due to its structural properties, chitosan does not only serve as a stabilizing matrix for the zinc oxide nanoparticles and vancomycin, but also plays an active role in the interaction with bacterial cell surfaces. In this way, it significantly enhances the overall antimicrobial performance of the nanocomposite.

Green Synthesis of Zinc Oxide Nanoparticles

Another key advantage lies in the production of the ZnO nanoparticles. These were synthesized using the probiotic bacterium Bacillus licheniformis, without the use of toxic chemicals. This so-called green synthesis method is not only environmentally friendly, but also results in biologically active nanoparticle surfaces that further increase antimicrobial performance.

Impressive Efficacy Against Bacteria and Fungi

The antimicrobial activity of the nanocomposite was tested against several clinically relevant pathogens with remarkable results:

While chitosan alone did not show clear inhibition zones, it significantly boosted the antimicrobial effect of vancomycin and ZnO in the combined system. In the case of Candida albicans, the nanocomposite was clearly superior to the antifungal drug fluconazole – at only one-sixth of the concentration.

Application Potential in Medicine and Technology

Thanks to its high efficacy at low doses and its good biocompatibility, the VA/ZnO/CS nanocomposite is particularly suitable for:

• antimicrobial wound dressings
• antimicrobial surfaces in clinical environments
• pharmaceutical formulations
• infection prevention in medical devices

The combination of enhanced activity, stability and sustainable production makes this system a highly promising candidate for sensitive applications in which conventional antibiotics often reach their limits.

Conclusion: Chitosan as an Active Component of Future Therapies
This study once again demonstrates the outstanding potential of high-quality chitosan. With its unique combination of bioavailability, antimicrobial activity and carrier function, chitosan opens up entirely new possibilities in the fight against resistant pathogens.
For the development of comparable systems, the use of high-purity, GMP-compliant chitosan with well-defined specifications is essential – such as those offered by HMC+. Only with precisely tailored chitosan can the described effects be reliably reproduced.

Quelle
Mohamed I. Abou-Dobara, Zakaria A. M. Baka, Shimaa M. El-Salamony and Mohamed M. El-Zahed (2025): Enhanced antimicrobial efficacy of a vancomycin/zinc oxide/chitosan nanocomposite via Bacillus licheniformis-mediated biomodification, Discover Nano.

First published on 8th of January 2026

Revised on 8th of January 2026